WO2015041310A1 - 抗プロテインc抗体による出血性疾患の治療 - Google Patents
抗プロテインc抗体による出血性疾患の治療 Download PDFInfo
- Publication number
- WO2015041310A1 WO2015041310A1 PCT/JP2014/074789 JP2014074789W WO2015041310A1 WO 2015041310 A1 WO2015041310 A1 WO 2015041310A1 JP 2014074789 W JP2014074789 W JP 2014074789W WO 2015041310 A1 WO2015041310 A1 WO 2015041310A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- antibody
- mouse
- activated
- hemophilia
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present invention relates to a composition for treating bleeding disorders containing a substance that inhibits the activation of protein C. Specifically, the present invention relates to a composition containing an anti-protein C antibody that inhibits protein C activation as an active ingredient.
- Hemophilia A is a hemorrhagic disease caused by a congenital defect or dysfunction of blood coagulation factor VIII (FVIII) or blood coagulation factor IX (FIX).
- the former is called hemophilia A and the latter is called hemophilia B. Since both genes are present on the X chromosome and genetic abnormalities are transmitted by sexual recessive inheritance, more than 99% of affected individuals are male. The prevalence is approximately 1 per 10,000 births and the ratio of hemophilia A to hemophilia B is known to be approximately 5: 1.
- Main bleeding sites include intra-articular, intramuscular, subcutaneous, intraoral, intracranial, gastrointestinal tract, and nasal cavity.
- repeated bleeding into the joint has progressed to hemophilic arthropathy with joint disorders and difficulty walking, and eventually joint replacement may be necessary. This is a major factor for the decline.
- the severity of hemophilia is defined by FVIII activity or FIX activity in the blood. Patients with less than 1% activity are severe, patients with 1% or more but less than 5% are moderate, patients with 5% or more but less than 40% The patient is classified as mild. Severe patients, which account for about 60% of hemophilia patients, have bleeding episodes several times a month, which is significantly more frequent than moderate and mild patients. For this reason, in patients with severe hemophilia, maintaining FVIII activity or FIX activity in blood at 1% or more is considered to be effective in preventing the onset of bleeding symptoms (Non-patent Document 1).
- vWF Von Willebrand factor
- blood coagulation factors purified from plasma or produced by gene recombination techniques are mainly used.
- Blood coagulation factors are not long-lasting (half-life is several hours to several tens of hours).
- the blood half-life of FVIII preparations and FIX preparations is about 12 hours and 24 hours, respectively. Therefore, for continuous prevention, it is necessary to administer the FVIII preparation about 3 times a week or the FIX preparation about twice a week. This corresponds to maintaining approximately 1% or more as FVIII activity or FIX activity. It has been reported that this prophylactic administration can prevent haemophilic joint disorders caused by frequent intra-articular bleeding, and as a result, greatly contributes to improving QOL of hemophilia A patients.
- blood clotting factors have the disadvantage of requiring intravenous administration.
- inhibitors antibodies against FVIII or FIX, called inhibitors, may develop in hemophilia patients, particularly severe hemophilia patients.
- an inhibitor When an inhibitor is generated, the effect of the coagulation factor formulation is hindered by the inhibitor.
- neutralization therapy using a large amount of coagulation factor preparation or bypass therapy using complex concentrate or activated blood coagulation factor VII (FVIIa preparation) is performed.
- hemostasis management for patients becomes very difficult, for example, because periodic supplement prevention has not been established. Therefore, there has been a strong demand for drugs that are not affected by the presence of inhibitors.
- antibodies are attracting attention and applied as pharmaceuticals because they are highly stable in blood, can be administered subcutaneously, and have low antigenicity.
- Antibodies are considered useful for the creation of pharmaceuticals because (i) wide dosing intervals, (ii) simple administration, and (iii) independent of the presence of inhibitors.
- the blood half-life of antibodies is generally relatively long, from days to weeks.
- antibodies migrate into the blood after subcutaneous administration.
- it has a structure that is significantly different from FVIII and FIX, and has low antigenicity. That is, the antibody drug satisfies the above (i), (ii), and (iii).
- PC protein C
- APC activated protein C
- EPCR endothelial protein C receptor
- Non-Patent Document 5 has been reported that an antibody that inhibits the activity of APC exhibits a blood coagulation effect and can be used for the treatment of hemophilia.
- the present invention is to provide a novel hemorrhagic disease treatment composition, anticoagulant action inhibiting composition or hemostatic action promoting composition having an excellent blood coagulation effect.
- a pharmaceutical composition for treating bleeding disorders comprising a protein C activation inhibitor.
- the hemorrhagic disease is a disease selected from hemophilia, acquired hemophilia, and von Willebrand disease or acquired von Willebrand disease caused by dysfunction or deficiency of vWF Composition.
- a pharmaceutical composition for promoting hemostasis comprising a protein C activation inhibitor.
- the hemostatic action is an effect on hemorrhagic symptoms of diseases selected from hemophilia, acquired hemophilia, and von Willebrand disease or acquired von Willebrand disease caused by dysfunction or deficiency of vWF.
- the composition according to [4] The composition according to [4].
- the composition according to [4], wherein the hemostatic effect is an effect on hemorrhagic symptoms of hemophilia A.
- a pharmaceutical composition for inhibiting an anticoagulant action comprising a protein C activation inhibitor.
- the composition according to [7], wherein the anticoagulant action is an anticoagulant action of activated protein C.
- pharmaceutical composition is a composition used in combination with an activated protein C activity inhibitor.
- the protein C activation inhibitor is an anti-protein C antibody.
- the anti-protein C antibody is an antibody that binds to the heavy chain of protein C.
- An anti-protein C antibody having an action of binding to the heavy chain of protein C and inhibiting the conversion of protein C to activated protein C.
- a method for treating a bleeding disorder comprising a step of administering a protein C activation inhibitor.
- the hemorrhagic disease is a disease selected from hemophilia, acquired hemophilia and von Willebrand disease or acquired von Willebrand disease caused by vWF dysfunction or defect the method of.
- the method according to [15], wherein the hemorrhagic disease is hemophilia A.
- a method for promoting hemostasis comprising a step of administering a protein C activation inhibitor.
- the hemostatic action is an effect on bleeding symptoms of a disease selected from hemophilia, acquired hemophilia, and von Willebrand disease or acquired von Willebrand disease caused by vWF dysfunction or deficiency, [18] The method described in [18]. [20] The method according to [18], wherein the hemostatic effect is an effect on hemorrhagic symptoms of hemophilia A. [21] A method for inhibiting an anticoagulant action, comprising a step of administering a protein C activation inhibitor. [22] The method according to [21], wherein the anticoagulant action is an anticoagulant action of activated protein C.
- the hemorrhagic disease is a disease selected from hemophilia, acquired hemophilia and von Willebrand disease or acquired von Willebrand disease caused by vWF dysfunction or defect Use of. [29] The use according to [27], wherein the hemorrhagic disease is hemophilia A. [30] Use of a protein C activation inhibitor for producing a drug for promoting hemostasis. [31] The hemostatic action is an effect on hemorrhagic symptoms of diseases selected from hemophilia, acquired hemophilia, and von Willebrand disease or acquired von Willebrand disease caused by vWF dysfunction or deficiency, [30] The use according to [30].
- the hemorrhagic disease is a disease selected from hemophilia, acquired hemophilia, and von Willebrand disease or acquired von Willebrand disease caused by vWF dysfunction or defect Substance.
- the substance according to [39], wherein the hemorrhagic disease is hemophilia A.
- the hemostatic action is an effect on hemorrhagic symptoms of diseases selected from hemophilia, acquired hemophilia, and von Willebrand disease or acquired von Willebrand disease caused by dysfunction or deficiency of vWF.
- the substance according to [42], wherein the hemostatic effect is an effect on hemorrhagic symptoms of hemophilia A.
- the substance according to [45], wherein the anticoagulant action is an anticoagulant action of activated protein C.
- the substance according to any of [39] to [46], wherein the protein C activation inhibitor further inhibits the activity of activated protein C.
- the broken line is the data of plasma without protein C activator (Protac) and without antibody.
- the inhibitory activity against the anticoagulant action of activated protein C is stronger as Lag time on the vertical axis is shortened or PeakPheight is increased than in the antibody non-added group (0 ⁇ g / mL).
- Lag time when protein C activator was added was shortened and Peak height added with protein C activator was increased in a concentration-dependent manner for both MP35 ( ⁇ ) and MP51 ( ⁇ ) From these results, it was shown that MP35 and MP51 have an activity of inhibiting the anticoagulant action of activated protein C.
- the present invention provides a pharmaceutical composition for treating bleeding disorders, which comprises a protein C activation inhibitor.
- inhibitortion of protein C activation refers to thrombin complexed with thrombomodulin. It means inhibiting protein C degradation.
- the substance that inhibits the activation of protein C include a substance that inhibits the binding between protein C and thrombin. Specific examples include anti-protein C antibody, anti-thrombin antibody, anti-thrombomodulin antibody, protein C partial peptide, thrombin partial peptide, thrombomodulin partial peptide, and low molecular weight compounds having the same activity as these.
- an anti-protein C antibody can be mentioned.
- an antibody refers to an immunoglobulin that is naturally occurring or produced by partial or complete synthesis.
- the antibody can be isolated from natural resources such as plasma and serum in which it naturally exists, or from the culture supernatant of hybridoma cells producing the antibody, or partially or completely by using techniques such as genetic recombination Can be synthesized.
- Preferred examples of antibodies include immunoglobulin isotypes and subclasses of those isotypes.
- human immunoglobulins nine classes (isotypes) of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, and IgM are known. Of these isotypes, IgG1, IgG2, IgG3, and IgG4 are preferred for the antibody of the present invention.
- a method for producing an antibody having a desired binding activity is known to those skilled in the art.
- a method for producing an antibody that binds to protein C is exemplified, but the method is not limited thereto.
- the anti-protein C antibody can be obtained as a polyclonal or monoclonal antibody using known means.
- a mammal-derived monoclonal antibody can be suitably prepared.
- Mammal-derived monoclonal antibodies include those produced by hybridomas and those produced by host cells transformed with expression vectors containing antibody genes by genetic engineering techniques.
- the monoclonal antibodies of the present invention include “humanized antibodies” and “chimeric antibodies”.
- Monoclonal antibody-producing hybridomas can be prepared, for example, as follows by using known techniques. That is, using a protein C protein as a sensitizing antigen, a mammal is immunized according to a normal immunization method. The resulting immune cells are fused with known parental cells by conventional cell fusion methods. Next, hybridomas that produce anti-protein C antibodies can be selected by screening monoclonal antibody-producing cells that bind to an epitope in the protein C molecule by conventional screening methods.
- Monoclonal antibodies are produced, for example, as shown below.
- a suitable host cell is transformed by inserting a gene sequence encoding protein C into a known expression vector.
- the desired protein C protein is purified from the host cell or culture supernatant by a known method.
- the purified protein C protein can be used as a sensitizing antigen used for immunization against mammals.
- Protein C partial peptides can also be used as sensitizing antigens.
- the partial peptide can also be obtained from the amino acid sequence of protein C by chemical synthesis. It can also be obtained by incorporating a part of the protein C gene into an expression vector for expression.
- the region and size of protein C peptide used as a partial peptide are not particularly limited to a specific embodiment.
- a preferred binding region for the anti-protein C antibody to inhibit the activation of protein C includes protein C heavy chain.
- a portion involved in binding to thrombin is preferable, and specifically, an activation peptide in the heavy chain or an epitope present in the vicinity thereof is preferable.
- the epitope present in the vicinity means that, when an anti-protein C antibody binds to protein C, it is within a range in which the binding between thrombin and protein C can be three-dimensionally inhibited.
- an antibody can inhibit the conversion of protein C to activated protein C. Therefore, in the present invention, an arbitrary sequence is preferably selected from amino acid sequences corresponding to the heavy chain of protein C and used as a sensitizing antigen.
- the number of amino acids constituting the peptide to be sensitized antigen is preferably at least 5 or more, for example 6 or more, or 7 or more. More specifically, a peptide having 8 to 50, preferably 10 to 30 residues can be used as a sensitizing antigen.
- a fusion protein obtained by fusing a desired partial polypeptide or peptide of protein C protein with a different polypeptide can be used as a sensitizing antigen.
- an antibody Fc fragment or a peptide tag can be suitably used.
- a vector that expresses a fusion protein can be prepared by fusing genes encoding two or more desired polypeptide fragments in-frame and inserting the fusion gene into an expression vector as described above. The method for producing the fusion protein is described in Molecular® Cloning® 2nd® ed. (Sambrook, Jet et al., “Molecular® Cloning® 2nd® ed.,” 9.47-9.58 (1989) Cold® Spring® Labor® Lab.® press).
- the mammal immunized with the sensitizing antigen is not limited to a specific animal, but is preferably selected in consideration of compatibility with the parent cell used for cell fusion.
- rodent animals eg, mice, rats, hamsters
- rabbits, monkeys, and the like are preferably used.
- the above animals are immunized with a sensitizing antigen.
- immunization is performed by administering a sensitizing antigen by intraperitoneal or subcutaneous injection of a mammal.
- a sensitized antigen diluted with PBS (Phosphate-Buffered Saline) or physiological saline at an appropriate dilution ratio is mixed with a normal adjuvant, for example, Freund's complete adjuvant, and emulsified, if desired.
- the sensitizing antigen is administered to the mammal several times every 4 to 21 days.
- an appropriate carrier can be used during immunization with the sensitizing antigen.
- a partial peptide having a low molecular weight when used as a sensitizing antigen, it may be desirable to immunize the sensitizing antigen peptide bound to a carrier protein such as albumin or keyhole limpet hemocyanin.
- a carrier protein such as albumin or keyhole limpet hemocyanin.
- a hybridoma that produces a desired antibody can be prepared as follows using DNA immunization.
- DNA immunization a sensitized antigen is expressed in vivo in the immunized animal to which the vector DNA constructed in such a manner that the gene encoding the antigen protein can be expressed in the immunized animal.
- This is an immunization method in which immune stimulation is given.
- DNA immunization is expected to have the following advantages. -Maintaining the structure of the protein and providing immune stimulation-No need to purify immune antigens
- DNA expressing protein C protein is first administered to an immunized animal.
- DNA encoding protein C can be synthesized by a known method such as PCR.
- the obtained DNA is inserted into an appropriate expression vector and administered to an immunized animal.
- the expression vector for example, a commercially available expression vector such as pcDNA3.1 can be suitably used.
- a method for administering a vector to a living body a generally used method can be used. For example, DNA immunization is performed by introducing gold particles adsorbed with an expression vector into cells of an immunized animal individual using a gene gun.
- immune cells are collected from the mammal and subjected to cell fusion. Spleen cells can be used as preferred immune cells.
- Mammalian myeloma cells are used as the cells fused with the immune cells.
- the myeloma cell is preferably provided with an appropriate selection marker for screening.
- a selectable marker refers to a trait that can (or cannot) survive under certain culture conditions.
- Known selection markers include hypoxanthine-guanine-phosphoribosyltransferase deficiency (hereinafter abbreviated as HGPRT deficiency) or thymidine kinase deficiency (hereinafter abbreviated as TK deficiency).
- HGPRT deficiency hypoxanthine-guanine-phosphoribosyltransferase deficiency
- TK deficiency thymidine kinase deficiency
- Cells having HGPRT or TK deficiency have hypoxanthine-aminopterin-thymidine sensitivity (hereinafter abbreviated as HAT sensitivity).
- HGPRT-deficient or TK-deficient cells can be selected in media containing 6 thioguanine, 8 azaguanine, or 5 'bromodeoxyuridine, respectively. Normal cells that incorporate these pyrimidine analogs into DNA die. On the other hand, cells deficient in these enzymes that cannot take up these pyrimidine analogs can survive in selective media.
- a selectable marker called G418 resistance confers resistance to 2-deoxystreptamine antibiotics (gentamicin analogs) by a neomycin resistance gene.
- Various myeloma cells suitable for cell fusion are known.
- Examples of such myeloma cells include P3 (P3x63Ag8.653) (J.JImmunol. (1979) 123 (4), 1548-1550), P3x63Ag8U.1 (Current Topics in Microbiology and Immunology (1978) 81, 1- 7), NS-1 (C. Eur. J. Immunol. (1976) 6 (7), 511-519), MPC-11 (Cell (1976) 8 (3), 405-415), SP2 / 0 ( Nature (1978) 276 (5685), 269-270), FO (J. Immunol. Methods (1980) 35 (1-2), 1-21), S194 / 5.XX0.BU.1 (J. Exp. Med. (1978) 148 (1), 313-323), R210 (Nature (1979) 277 (5692), 131-133) and the like can be suitably used.
- P3x63Ag8.653 J.JImmunol. (1979) 123 (4)
- cell fusion between the immune cells and myeloma cells is performed according to a known method such as the method of Köhler and Milstein et al. (Methods Enzymol. (1981) 73, 3-46).
- the cell fusion can be carried out in a normal nutrient culture medium in the presence of a cell fusion promoter.
- a cell fusion promoter for example, polyethylene glycol (PEG), Sendai virus (HVJ) or the like is used, and an auxiliary agent such as dimethyl sulfoxide is optionally added to increase the fusion efficiency.
- the usage ratio of immune cells and myeloma cells can be set arbitrarily.
- the number of immune cells is preferably 1 to 10 times that of myeloma cells.
- the culture medium used for the cell fusion for example, RPMI1640 culture medium suitable for the growth of the myeloma cell line, MEM culture medium, and other normal culture liquids used for this type of cell culture are used. Serum replacement fluid such as fetal serum (FCS) can be suitably added.
- FCS fetal serum
- a predetermined amount of the immune cells and myeloma cells are mixed well in the culture solution, and a PEG solution (for example, an average molecular weight of about 1000 to 6000) preheated to about 37 ° C. is usually 30 to 60%. It is added at a concentration of (w / v).
- a desired fused cell is formed by gently mixing the mixture.
- cell fusion agents and the like that are undesirable for the growth of hybridomas can be removed by repeating the operation of adding the appropriate culture solution listed above and removing the supernatant by centrifugation.
- the hybridoma thus obtained can be selected by culturing in a normal selective culture solution, for example, a HAT culture solution (a culture solution containing hypoxanthine, aminopterin and thymidine).
- a HAT culture solution a culture solution containing hypoxanthine, aminopterin and thymidine.
- the culture using the HAT culture solution can be continued for a time sufficient for cells other than the desired hybridoma (non-fused cells) to die (usually the sufficient time is several days to several weeks).
- screening and single cloning of hybridomas producing the desired antibody are performed by the usual limiting dilution method.
- the hybridoma thus obtained can be selected by using a selective culture solution corresponding to the selection marker possessed by the myeloma used for cell fusion.
- a selective culture solution corresponding to the selection marker possessed by the myeloma used for cell fusion.
- cells having HGPRT or TK deficiency can be selected by culturing in a HAT culture solution (a culture solution containing hypoxanthine, aminopterin and thymidine). That is, when HAT-sensitive myeloma cells are used for cell fusion, cells that have succeeded in cell fusion with normal cells can selectively proliferate in the HAT medium.
- the culture using the HAT culture solution is continued for a time sufficient for cells other than the desired hybridoma (non-fusion cells) to die.
- a desired hybridoma can be selected by culturing for several days to several weeks. Subsequently, screening and single cloning of hybridomas producing the desired antibody can be performed by conventional limiting
- Desired antibody screening and single cloning can be suitably performed by a screening method based on a known antigen-antibody reaction.
- the binding activity of an antibody to labeled protein C protein can be evaluated based on the principle of ELISA.
- protein C protein is immobilized on the well of an ELISA plate.
- the culture supernatant of the hybridoma is brought into contact with the immobilized protein in the well, and an antibody that binds to the immobilized protein is detected.
- the monoclonal antibody is derived from a mouse, the antibody bound to the cell can be detected by an anti-mouse immunoglobulin antibody.
- a hybridoma that produces a desired antibody having an ability to bind to an antigen selected by these screenings can be cloned by a limiting dilution method or the like.
- the hybridoma producing the monoclonal antibody thus produced can be subcultured in a normal culture solution.
- the hybridoma can be stored for a long time in liquid nitrogen.
- the hybridoma is cultured according to a usual method, and a desired monoclonal antibody can be obtained from the culture supernatant.
- a hybridoma can be administered to a mammal compatible therewith and allowed to proliferate, and a monoclonal antibody can be obtained from the ascites.
- the former method is suitable for obtaining a highly pure antibody.
- An antibody encoded by an antibody gene cloned from antibody-producing cells such as the hybridoma can also be suitably used.
- An antibody encoded by the gene is expressed by incorporating the cloned antibody gene into a suitable vector and introducing it into a host. Methods for isolation of antibody genes, introduction into vectors, and transformation of host cells have already been established, for example, by Vandamme et al. (Eur. J. Biochem. (1990) 192 (3), 767 -775). As described below, methods for producing recombinant antibodies are also known.
- cDNA encoding a variable region (V region) of an anti-protein C antibody is obtained from a hybridoma cell that produces an anti-protein C antibody.
- RNA is extracted from the hybridoma.
- the following method can be used. -Guanidine ultracentrifugation (Biochemistry (1979) 18 (24), 5294-5299) -AGPC method (Anal. Biochem. (1987) 162 (1), 156-159)
- Extracted mRNA can be purified using mRNA Purification Kit (manufactured by GE Healthcare Bioscience). Alternatively, kits for extracting total mRNA directly from cells, such as QuickPrep mRNA Purification Kit (manufactured by GE Healthcare Bioscience), are also commercially available. Using such a kit, mRNA can be obtained from the hybridoma. CDNA encoding the antibody V region can be synthesized from the obtained mRNA using reverse transcriptase. cDNA can be synthesized by AMV Reverse Transcriptase First-strand cDNA Synthesis Kit (manufactured by Seikagaku Corporation). In addition, for cDNA synthesis and amplification, 5'-RACE method using Proc. Natl. Acad.
- the desired cDNA fragment is purified from the obtained PCR product and then ligated with vector DNA.
- a recombinant vector is produced, introduced into Escherichia coli or the like and a colony is selected, a desired recombinant vector can be prepared from Escherichia coli that has formed the colony. Then, whether or not the recombinant vector has the target cDNA base sequence is confirmed by a known method such as the dideoxynucleotide chain termination method.
- cDNA is synthesized using RNA extracted from hybridoma cells as a template to obtain a 5′-RACE cDNA library.
- a commercially available kit such as a SMART®RACE® cDNA amplification kit is appropriately used for the synthesis of the 5′-RACE® cDNA library.
- the antibody gene is amplified by PCR using the obtained 5′-RACE® cDNA library as a template.
- Primers for amplifying mouse antibody genes can be designed based on known antibody gene sequences. These primers have different nucleotide sequences for each immunoglobulin subclass. Therefore, it is desirable to determine the subclass in advance using a commercially available kit such as IsoIStrip mouse monoclonal antibody isotyping kit (Roche Diagnostics).
- primers capable of amplifying genes encoding ⁇ 1, ⁇ 2a, ⁇ 2b, ⁇ 3 as heavy chains and ⁇ and ⁇ chains as light chains are provided. Can be used.
- a primer that anneals to a portion corresponding to a constant region close to the variable region is generally used as the 3 ′ primer.
- the primer attached to the 5 ′ RACE cDNA library preparation kit is used as the 5 ′ primer.
- an immunoglobulin comprising a combination of a heavy chain and a light chain
- Desired antibodies can be screened using the binding activity of the reconstituted immunoglobulin to protein C as an index.
- the binding of the antibody to protein C is more preferably specific.
- Antibodies that bind to protein C can be screened, for example, as follows; (1) contacting an antibody comprising a V region encoded by cDNA obtained from a hybridoma with protein C; (2) detecting the binding between protein C and an antibody, and (3) selecting an antibody that binds to protein C.
- Methods for detecting the binding between antibody and protein C are known. Specifically, the binding between the antibody and protein C can be detected by a technique such as ELISA described above. In order to evaluate the binding activity of the antibody, a protein C-fixed specimen can be appropriately used.
- a panning method using a phage vector is also preferably used as an antibody screening method using binding activity as an index.
- an antibody gene is obtained from a polyclonal antibody-expressing cell group as a heavy chain and light chain subclass library
- a screening method using a phage vector is advantageous.
- Genes encoding the variable regions of the heavy chain and the light chain can form a single chain Fv (scFv) by ligating with an appropriate linker sequence.
- scFv single chain Fv
- the phage encoding the antigen can be recovered to recover the DNA encoding scFv having the desired binding activity. By repeating this operation as necessary, scFv having a desired binding activity can be concentrated.
- the cDNA is digested with a restriction enzyme that recognizes restriction enzyme sites inserted at both ends of the cDNA.
- a preferred restriction enzyme recognizes and digests a base sequence that appears infrequently in the base sequence constituting the antibody gene.
- a restriction enzyme that gives a sticky end.
- An antibody expression vector can be obtained by inserting a cDNA encoding the V region of the anti-protein C antibody digested as described above into an appropriate expression vector.
- a chimeric antibody refers to an antibody having a different origin from the constant region and the variable region. Accordingly, in addition to a heterologous chimeric antibody such as mouse-human, a human-human homologous chimeric antibody is also included in the chimeric antibody of the present invention.
- a chimeric antibody expression vector can be constructed by inserting the V region gene into an expression vector having a constant region in advance.
- a restriction enzyme recognition sequence for a restriction enzyme that digests the V region gene can be appropriately arranged on the 5 ′ side of an expression vector holding a DNA encoding a desired antibody constant region (C region).
- a chimeric antibody expression vector is constructed by fusing both digested with the same combination of restriction enzymes in-frame.
- Antibody isotype is determined by the structure of the antibody constant region.
- the antibody constant regions of the IgG1, IgG2, IgG3, and IgG4 isotypes are called C ⁇ 1, C ⁇ 2, C ⁇ 3, and C ⁇ 4, respectively.
- the constant region of the ⁇ and ⁇ chain is appropriately used as the antibody constant region of the light chain.
- the antibody gene is incorporated into an expression vector so that it is expressed under the control of the expression control region.
- An expression control region for expressing an antibody includes, for example, an enhancer and a promoter.
- An appropriate signal sequence can also be added to the amino terminus so that the expressed antibody is secreted extracellularly.
- the expressed polypeptide can be cleaved at the carboxyl terminal portion of the sequence, and the cleaved polypeptide can be secreted extracellularly as a mature polypeptide.
- an appropriate host cell is transformed with this expression vector, whereby a recombinant cell expressing a DNA encoding an anti-protein C antibody can be obtained.
- DNAs encoding antibody heavy chains (H chains) and light chains (L chains) are each incorporated into separate expression vectors.
- An antibody molecule having an H chain and an L chain can be expressed by co-transfecting the same host cell with a vector in which an H chain and an L chain are incorporated.
- host cells can be transformed by incorporating DNAs encoding H and L chains into a single expression vector (see WO1994 / 011523).
- host cells and expression vectors for producing antibodies by introducing an isolated antibody gene into a suitable host are known. Any of these expression systems can be applied to isolate the antigen binding domain of the present invention.
- animal cells, plant cells, or fungal cells can be used as appropriate. Specifically, the following cells can be exemplified as animal cells.
- Mammalian cells CHO, COS, myeloma, BHK (baby hamster kidney), Hela, Vero, HEK (human embryonic kidney) 293, etc.
- Amphibian cells Xenopus oocytes, etc.
- Insect cells sf9, sf21, Tn5, etc.
- Nicotiana such as Nicotiana tabacum
- Callus cultured cells can be used as appropriate for transformation of plant cells.
- -Yeast Saccharomyces genus such as Saccharomyces serevisiae, Pichia genus such as methanol-utilizing yeast (Pichia pastoris)-Filamentous fungi: Aspergillus genus such as Aspergillus niger
- antibody gene expression systems using prokaryotic cells are also known.
- bacterial cells such as E. coli and Bacillus subtilis can be appropriately used.
- An expression vector containing the target antibody gene is introduced into these cells by transformation. By culturing the transformed cells in vitro, a desired antibody can be obtained from the culture of the transformed cells.
- transgenic animals can also be used for the production of recombinant antibodies. That is, the antibody can be obtained from an animal into which a gene encoding a desired antibody has been introduced.
- an antibody gene can be constructed as a fusion gene by inserting it in-frame into a gene encoding a protein that is uniquely produced in milk.
- a protein secreted into milk for example, goat ⁇ casein can be used.
- the DNA fragment containing the fusion gene into which the antibody gene has been inserted is injected into a goat embryo, and the injected embryo is introduced into a female goat.
- the desired antibody can be obtained as a fusion protein with milk protein from milk produced by a transgenic goat (or its progeny) born from a goat that has received the embryo.
- hormones can be administered to transgenic goats to increase the amount of milk containing the desired antibody produced from the transgenic goat (Bio / Technology (1994), 12 (7), 699-702). .
- the antigen-binding domain of the antibody is derived from a genetically engineered antibody that has been artificially modified for the purpose of reducing heteroantigenicity against humans
- the recombinant antibody includes, for example, a humanized antibody. These modified antibodies are appropriately produced using known methods.
- variable region of an antibody used for the production of an antigen-binding domain in the anti-protein C antibody of the present invention usually has three complementarity-determining regions (CDRs) sandwiched between four framework regions (FR). It consists of CDRs are regions that substantially determine the binding specificity of an antibody.
- CDRs complementarity-determining regions
- FR framework regions
- the amino acid sequence of CDR is rich in diversity. On the other hand, the amino acid sequence constituting FR often shows high identity even among antibodies having different binding specificities. Therefore, it is generally said that the binding specificity of a certain antibody can be transplanted to another antibody by CDR grafting.
- Humanized antibodies are also referred to as reshaped human antibodies.
- non-human animals for example, humanized antibodies obtained by grafting mouse antibody CDRs to human antibodies are known.
- General genetic recombination techniques for obtaining humanized antibodies are also known.
- overlap extension PCR overlap extension PCR
- a base sequence encoding the CDR of a mouse antibody to be transplanted is added to a primer for synthesizing the FR of a human antibody. Primers are prepared for each of the four FRs.
- a human FR comprising an amino acid sequence having high identity with the FR amino acid sequence adjacent to the mouse CDR to be transplanted.
- the base sequences to be linked are designed to be connected to each other in frame.
- Human FRs are synthesized individually by each primer.
- a product in which DNA encoding mouse CDR is added to each FR is obtained.
- the base sequences encoding mouse CDRs of each product are designed to overlap each other.
- the overlapping CDR portions of the products synthesized using the human antibody gene as a template are annealed with each other to perform a complementary chain synthesis reaction. By this reaction, human FRs are linked via the mouse CDR sequence.
- a human antibody expression vector can be prepared by inserting the DNA obtained as described above and a DNA encoding the human antibody C region into an expression vector so as to be fused in frame. After the recombinant vector is established by introducing the integration vector into the host, the recombinant cell is cultured, and the humanized antibody is expressed by expressing the DNA encoding the humanized antibody. (See European Patent Publication EP239400, International Publication WO1996 / 002576).
- the CDR forms a favorable antigen-binding site when linked via CDR.
- a human antibody FR can be suitably selected.
- FR amino acid residues can be substituted so that the CDR of the reshaped human antibody forms an appropriate antigen-binding site.
- amino acid sequence mutations can be introduced into FRs by applying the PCR method used for transplantation of mouse CDRs into human FRs.
- partial nucleotide sequence mutations can be introduced into primers that anneal to the FR.
- a nucleotide sequence mutation is introduced into the FR synthesized by such a primer.
- a mutant FR sequence having a desired property can be selected by measuring and evaluating the antigen-binding activity of a mutant antibody substituted with an amino acid by the above method (Cancer Res., (1993) 53, 851-856).
- transgenic animals having all repertoires of human antibody genes are used as immunized animals, and DNA immunization is performed. Desired human antibodies can be obtained.
- the V region of a human antibody is expressed as a single chain antibody (scFv) on the surface of the phage by the phage display method.
- Phages expressing scFv that bind to the antigen can be selected.
- the DNA sequence encoding the V region of the human antibody that binds to the antigen can be determined.
- the V region sequence is fused in-frame with the sequence of the desired human antibody C region, and then inserted into an appropriate expression vector, whereby an expression vector can be prepared.
- the human antibody is obtained by introducing the expression vector into a suitable expression cell as described above and expressing the gene encoding the human antibody.
- These methods are already known (see International Publications WO1992 / 001047, WO1992 / 020791, WO1993 / 006213, WO1993 / 011236, WO1993 / 019172, WO1995 / 001438, WO1995 / 015388).
- Whether or not protein C activation is inhibited can be confirmed according to a known method. For example, after contacting a candidate substance that inhibits the activation of protein C with protein C, thrombin and thrombomodulin are added to initiate the activation reaction of protein C by thrombin. Thereafter, the protein C activation reaction is stopped. By measuring the activity of protein C activated by thrombin, it can be confirmed whether the candidate substance inhibits the activation of protein C. Specifically, as described in Example 4.
- the protein C activation inhibitor obtained by the above method can be formulated into a pharmaceutical composition according to a conventional method.
- the pharmaceutical composition of the present invention may be used in combination with a substance that inhibits the activity of activated protein C, and the protein C activation inhibitor simultaneously activates activated protein C. It may have an inhibitory activity.
- “inhibition of activated protein C activity” or “inhibit activated protein C activity” means inactivation of activated coagulation factor V or activated coagulation factor VIII by activated protein C. Means to inhibit.
- the substance that inhibits the activity of activated protein C include a substance that inhibits the binding between activated protein C and activated coagulation factor V or activated coagulation factor VIII.
- the partial peptide of coagulation factor VIII include low molecular weight compounds exhibiting the same activity as these.
- “use in combination with a substance that inhibits the activity of activated protein C” means that a substance that inhibits the activation of protein C and a substance that inhibits the activity of activated protein C are simultaneously separated separately. Or it means combining to administer sequentially.
- the substance that inhibits the activation of protein C and the substance that inhibits the activity of activated protein C may be contained in one pharmaceutical composition or may be contained in separate pharmaceutical compositions.
- the kit may include a pharmaceutical composition containing a substance that inhibits the activation of protein C and a pharmaceutical composition containing a substance that inhibits the activity of activated protein C.
- the substance that inhibits the activation of protein C and the substance that simultaneously inhibits the activity of activated protein C include antibodies. Specifically, for example, among the above-mentioned anti-protein C antibodies, antibodies having an action of inhibiting the activity of activated protein C can be mentioned as preferable antibodies. More specifically, antibodies that bind to protein C and activated protein C can be mentioned.
- activated protein C Whether or not the activity of activated protein C is inhibited can be confirmed according to a known method. For example, after a candidate substance that inhibits the activity of activated protein C is brought into contact with activated protein C, activated coagulation factor V is added, and activated protein C inactivates the activated coagulation factor V. To start. After that, by adding activated blood coagulation factor X and prothrombin, activated thrombin generation dependent on activated coagulation factor V is started, and by measuring the activity of the generated thrombin, the candidate substance is activated. Whether protein C inactivation is inhibited can be confirmed. Specifically, as described in Example 3.
- activated protein C since the substance that inhibits the activation of protein C has the action of inhibiting the anticoagulant action by activated protein C and promoting blood coagulation, activated protein C It can be used to inhibit the anticoagulant action due to or to promote the hemostatic action. Moreover, it can utilize for the treatment of the hemorrhagic disease resulting from the fall of a blood coagulation function by the effect
- vWF von Willebrand disease
- the present invention provides a pharmaceutical composition for inhibiting an anticoagulant action, a pharmaceutical composition for promoting a hemostatic action, or a treatment for bleeding disorders, which contains a protein C activation inhibitor.
- a pharmaceutical composition is provided.
- the pharmaceutical composition of the present invention can be administered to a patient by either oral or parenteral administration. Preferably, it is parenteral administration. Specific examples of such administration methods include injection administration, nasal administration, transpulmonary administration, and transdermal administration.
- injection administration the pharmaceutical composition of the present invention can be administered systemically or locally by, for example, intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection and the like.
- the administration method can be appropriately selected depending on the age and symptoms of the patient.
- the dose for example, the dose can be selected in the range of 0.0001 mg to 1000 mg per kg of body weight per administration. Alternatively, for example, the dose can be selected in the range of 0.001 to 100,000 mg / body per patient.
- the pharmaceutical composition of the present invention is not limited to these doses.
- the pharmaceutical composition of the present invention can be formulated in accordance with a conventional method (for example, Remington's Pharmaceutical, Science, Latest Edition, Mark Publishing, Company, Easton, USA) together with pharmaceutically acceptable carriers and additives. It may be.
- Pharmaceutically acceptable carriers and additives include, for example, surfactants, excipients, colorants, flavoring agents, preservatives, stabilizers, buffers, suspending agents, isotonic agents, binders, disintegrations. Agents, lubricants, fluidity promoters, flavoring agents and the like. Furthermore, it is not restricted to these, Other commonly used carriers and additives can be used as appropriate.
- silicic acid lactose, crystalline cellulose, mannitol, starch, carmellose calcium, carmellose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylacetal diethylaminoacetate, polyvinylpyrrolidone, gelatin, medium chain fatty acid triglyceride
- the carrier include polyoxyethylene hydrogenated castor oil 60, sucrose, carboxymethylcellulose, corn starch, and inorganic salts.
- the antibody of the present invention may be encapsulated in microcapsules (microcapsules such as hydroxymethylcellulose, gelatin, poly [methylmethacrylic acid]) or colloid drug delivery systems (liposomes, albumin microspheres, microemulsions, nanoparticles). And nanocapsules, etc. (see “Remington's Pharmaceutical Science 16th edition", “Oslo Ed.” (1980), etc.).
- a method of making a drug into a sustained-release drug is also known and can be applied to the antibody of the present invention (Langer et al., J. Biomed. Mater. Res. 15: 267-277 (1981); Langer, Chemtech. 12: 98-105 (1982); US Pat. No. 3,773,919; European Patent Application Publication (EP) 58,481; Sidman et al., Biopolymers 22: 547-556 (1983); EP 133,988).
- microcapsules such as hydroxymethylcellulose, gelatin, poly [methyl
- the present invention also provides a method for preventing and / or treating bleeding, bleeding-related diseases, or diseases caused by bleeding, comprising the step of administering the antibody or composition of the present invention.
- Administration of the antibody or composition can be carried out, for example, by the method described above.
- the present invention provides a kit for use in the above method, comprising at least the antibody or composition of the present invention.
- the kit can be packaged with a syringe barrel, a needle, a pharmaceutically acceptable medium, an alcohol cotton cloth, an adhesive bandage, or instructions describing how to use the kit.
- the present invention also relates to the use of the pharmaceutical composition comprising the protein C activation inhibitor of the present invention in the production of a preventive and / or therapeutic agent for bleeding, bleeding-related diseases or diseases caused by bleeding.
- the present invention also relates to a multispecific antigen-binding molecule or bispecific antibody or composition of the present invention for the prevention and / or treatment of bleeding, bleeding-related diseases or diseases caused by bleeding. It should be noted that all prior art documents cited in the present specification are incorporated herein by reference.
- Example 1 Preparation of mouse protein C cDNA covering the full-length translation region of mouse protein C was amplified from mouse liver by PCR. Using this as a template, the gene was further amplified by the PCR method with a FLAG tag attached to the C-terminus and subcloned into an expression vector. The expression vector was transfected into CHO cells and cultured. Mouse protein C-Flag protein was purified from the obtained culture supernatant according to a conventional method.
- Example 2 Preparation of anti-mouse protein C rat antibody
- the mouse protein C-Flag protein (0.1 mg / animal) prepared in Example 1 was mixed with Freund's Complete Adjuvant (FCA, Difco Laboratories, now Becton Dickinson Co).
- FCA Freund's Complete Adjuvant
- the rats were inoculated into one footpad of SD rats (2 animals, Charles River Japan).
- Two weeks after inoculation iliac lymph nodes were removed from the immunized rats.
- a hybridoma was prepared using the extracted lymph node cells according to a conventional method. Using the culture supernatant of the hybridoma, the binding activity of the antibody produced by the hybridoma to mouse protein C-Flag and Flag protein was measured by ELISA.
- Hybridomas producing antibodies that specifically showed binding activity to mouse protein C were selected.
- the selected hybridoma was cultured, and anti-mouse protein C antibody was purified from the culture supernatant according to a conventional method.
- the purified antibody was screened by the methods described in Examples 3 and 4, and MP35 and MP51 were selected as antibodies that activate mouse protein C and / or inhibit activated protein C activity.
- Example 3 Effect (method) of anti-mouse protein C antibodies MP35 and MP51 on FVa inactivation by mouse activated protein C (1) Reagent preparation • Anti-mouse protein C antibody was prepared at 15, 50 ⁇ g / mL in Tris-buffered saline (TBSB) containing 0.1% bovine serum albumin. • Hirudin (Merck KgaA) was prepared at 10 IU / mL with TBSB.
- Mouse protein C-Flag, human ⁇ thrombin (Enzyme Research Laboratories), rabbit thrombomodulin (American Diagnostica), human activated coagulation factor X (FXa, Enzyme Research Laboratories), human activated coagulation factor V (FVa, Enzyme Research) Laboratories) and human prothrombin (Enzyme Research Laboratories) are available in 104 ⁇ M phospholipid solutions (10% phosphatidylserine / 60% phosphatidylcholine / 30% phosphatidylethanolamine (Avanti Polar Lipids); Lab. Haem.
- TBSB TBSB
- TBCP TBSB
- 8.3 mM CaCl 2 and 1.7 mM MgCl 2 24.8 ⁇ g / mL, 1.48 ⁇ g / mL, and 14.8 ⁇ g, respectively.
- / mL 9.66 ng / mL, 2.25 ng / mL and 50 ⁇ g / mL.
- mice activated protein C 24.8 ⁇ g / mL mouse protein C-Flag, 1.48 ⁇ g / mL human ⁇ -thrombin, and 14.8 ⁇ g / mL rabbit thrombomodulin were mixed in equal amounts and incubated at 37 ° C for 120 minutes.
- the anti-mouse protein C antibody MP35 or MP51 increased the absorbance (FIG. 1). Therefore, both MP35 and MP51 were shown to inhibit FVa inactivation by mouse activated protein C.
- Example 4 Effect of anti-mouse protein C antibodies MP35 and MP51 on mouse protein C activation by thrombin / thrombomodulin complex (method) (1) Preparation of Reagents • Anti-mouse protein C antibody and hirudin were prepared in TBSB at 120 ⁇ g / mL and 75 U / mL, respectively. -Mouse protein C-Flag, human ⁇ -thrombin and rabbit thrombomodulin were prepared in TBCP to 24.8 ⁇ g / mL, 14.8 ⁇ g / mL and 14.8 ⁇ g / mL, respectively. -Spectrozyme aPC (American Diagnostica) was dissolved in 5 mM with purified water and then diluted 6.25 times with purified water.
- Example 5 Effect of anti-mouse protein C antibody on thrombin generation in mouse plasma supplemented with protein C activator (method)
- Reagent preparation • Anti-mouse protein C antibody was prepared at 0.18, 0.6, 1.8, 6, 18, 60, and 180 ⁇ g / mL with TBSB.
- -Protein C activator product name Protac, American Diagnostica Inc was dissolved in purified water (6 U / mL) and further adjusted to 4 U / mL with TBS.
- the plate was set in a thrombin generation fluorescence system, and after incubation at 37 ° C. for about 5 minutes, measurement was started. (At the same time as the start of measurement, 20 ⁇ L of Fluo-Substrate and Fluo-Buffer mixed solution is added.)
- Thrombin Calibrator Thrombinoscope BV.
- the setting conditions of the thrombin generation fluorescence system dedicated analysis software Thrombinoscope software version 3.0.0.29 are as follows. ⁇ Fluo-Substrate and Fluo-Buffer mixed solution volume (Setting item Dispense): 20 ⁇ L ⁇ Agitation time (setting item Shake): 10 seconds ⁇ Measurement time (setting item Totaltime): 60 minutes ⁇ Measurement interval (setting item Interval): 20 seconds ⁇ Excitation wavelength (automatic setting): 390 nm ⁇ Fluorescence wavelength (automatic setting): 460 nm Using the calculated thrombin generation start time (Lag time (min)) and the maximum thrombin generation amount (Peak height (nmol / L)), the ability of anti-mouse protein C antibody to inhibit activated protein C activity in mouse plasma was evaluated. did.
- FIG. 3A The effect of anti-mouse protein C antibody on thrombin generation in normal mouse plasma supplemented with protein C activator (Protac) is shown in FIG. 3A.
- Protac protein C activator
- the Lag time was increased from 2.0 minutes to 2.4 minutes and the Peak height was reduced from 53 nM to 22 nM, so that activated protein C produced by Protac was It was confirmed to show a coagulation effect.
- Both the anti-mouse protein C antibodies MP35 and MP51 decreased Lag time and increased Peak height when Protac was added in a dose-dependent manner.
- FVIII-deficient mouse plasma was also evaluated (FIG. 3B).
- Example 8 Analysis of antigen binding site of anti-mouse protein C antibody (method) It was examined using Western blotting (WB) whether MP35 and MP51 recognize the light chain or heavy chain of mouse PC.
- Mouse PC [product name] Recombinant Mouse Coagulation Factor XIV / Protein C, [supplier] R & D Systems, [catalog number] 4885-SE) to human thrombin ([product name] Human alpha Thrombin, [supplier] Enzyme research laboratories , [Catalog No.
- Example 9 Preparation of anti-mouse protein C human antibody Using the mouse protein C protein prepared in Example 1, display phages that bind to mouse protein C were concentrated from the human naive antibody library by the phage display method. Select display phages that specifically bind to mouse protein C and amplify antibody variable region genes from them. It was expressed and purified as recombinant IgG according to a conventional method. The purified antibody was screened by the methods described in Examples 3 and 4 and L2 and L12 were selected as antibodies that activate mouse protein C and / or inhibit activated protein C activity.
- Example 10 Effect (method) of anti-mouse protein C antibodies L2 and L12 on FVa inactivation by mouse activated protein C
- the method of Example 3 was followed.
- Anti-mouse protein C antibody L2 or L12 increased the absorbance (FIG. 5).
- both L2 and L12 were shown to inhibit FVa inactivation by mouse activated protein C.
- the antibody concentration during mouse protein C activation reaction is 15 or 50 ⁇ g / mL.
- Example 11 Effect of anti-mouse protein C antibodies L2 and L12 on mouse protein C activation by thrombin / thrombomodulin complex (method) According to the method of Example 4. (result) The absorbance decreased with the addition of anti-mouse protein C antibody L12. On the other hand, even when L2 was added, there was no change in absorbance (FIG. 6). Thus, L12 was shown to inhibit protein C activation but not L2. The antibody concentration during mouse protein C activation reaction is 30 ⁇ g / mL.
- the present invention it has become possible to inhibit or suppress the anticoagulant action by protein C and promote the blood coagulation action / hemostatic action. Therefore, the present invention has made it possible to develop new therapeutic agents and new treatment methods for bleeding diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
従って、インヒビターの存在に左右されない薬剤が、強く求められていた。
また、APCの活性を阻害する抗体が血液凝固効果を示し、血友病の治療に利用できる可能性も報告されている(特許文献1)。
なお、本出願の発明に関連する先行技術文献情報を以下に示す。
〔1〕プロテインCの活性化阻害物質を含有する、出血性疾患を治療するための医薬組成物。
〔2〕出血性疾患が血友病、後天性血友病及び、vWFの機能異常又は欠損に起因するフォンビルブランド病又は後天性フォンビルブランド病から選ばれる疾患である、〔1〕に記載の組成物。
〔3〕出血性疾患が血友病Aである、〔1〕に記載の組成物。
〔4〕プロテインCの活性化阻害物質を含有する、止血作用を促進するための医薬組成物。
〔5〕止血作用が、血友病、後天性血友病及び、vWFの機能異常又は欠損に起因するフォンビルブランド病又は後天性フォンビルブランド病から選ばれる疾患の出血症状に対する作用である、〔4〕に記載の組成物。
〔6〕止血作用が、血友病Aの出血症状に対する作用である、〔4〕に記載の組成物。
〔7〕プロテインCの活性化阻害物質を含有する、抗血液凝固作用を阻害するための医薬組成物。
〔8〕抗血液凝固作用が、活性化プロテインCの抗血液凝固作用である、〔7〕に記載の組成物。
〔9〕プロテインCの活性化阻害物質が、さらに活性化プロテインCの活性を阻害する、〔1〕から〔8〕のいずれかに記載の組成物。
〔10〕医薬組成物が、活性化プロテインCの活性阻害物質と組み合わせて用いる組成物である、〔1〕から〔9〕のいずれかに記載の組成物。
〔11〕プロテインCの活性化阻害物質が、抗プロテインC抗体である、〔1〕から〔10〕のいずれかに記載の組成物。
〔12〕抗プロテインC抗体が、プロテインCの重鎖に結合する抗体である、〔11〕に記載の組成物。
〔13〕プロテインCの重鎖に結合し、プロテインCの活性化プロテインCへの変換を阻害する作用を有する、抗プロテインC抗体。
〔14〕抗プロテインC抗体が、さらに活性化プロテインCの活性を阻害する作用を有する、〔13〕に記載の抗体。
〔15〕プロテインCの活性化阻害物質を投与する工程を含む、出血性疾患を治療するための方法。
〔16〕出血性疾患が血友病、後天性血友病及び、vWFの機能異常又は欠損に起因するフォンビルブランド病又は後天性フォンビルブランド病から選ばれる疾患である、〔15〕に記載の方法。
〔17〕出血性疾患が血友病Aである、〔15〕に記載の方法。
〔18〕プロテインCの活性化阻害物質を投与する工程を含む、止血作用を促進するための方法。
〔19〕止血作用が、血友病、後天性血友病及び、vWFの機能異常又は欠損に起因するフォンビルブランド病又は後天性フォンビルブランド病から選ばれる疾患の出血症状に対する作用である、〔18〕に記載の方法。
〔20〕止血作用が、血友病Aの出血症状に対する作用である、〔18〕に記載の方法。
〔21〕プロテインCの活性化阻害物質を投与する工程を含む、抗血液凝固作用を阻害するための方法。
〔22〕抗血液凝固作用が、活性化プロテインCの抗血液凝固作用である、〔21〕に記載の方法。
〔23〕プロテインCの活性化阻害物質が、さらに活性化プロテインCの活性を阻害する、〔15〕から〔22〕のいずれかに記載の方法。
〔24〕活性化プロテインCの活性阻害物質と組み合わせて投与される、〔15〕から〔23〕のいずれかに記載の方法。
〔25〕プロテインCの活性化阻害物質が、抗プロテインC抗体である、〔15〕から〔24〕のいずれかに記載の方法。
〔26〕抗プロテインC抗体が、プロテインCの重鎖に結合する抗体である、〔25〕に記載の方法。
〔27〕出血性疾患を治療するための薬剤を製造するためのプロテインCの活性化阻害物質の使用。
〔28〕出血性疾患が血友病、後天性血友病及び、vWFの機能異常又は欠損に起因するフォンビルブランド病又は後天性フォンビルブランド病から選ばれる疾患である、〔27〕に記載の使用。
〔29〕出血性疾患が血友病Aである、〔27〕に記載の使用。
〔30〕止血作用を促進するための薬剤を製造するためのプロテインCの活性化阻害物質の使用。
〔31〕止血作用が、血友病、後天性血友病及び、vWFの機能異常又は欠損に起因するフォンビルブランド病又は後天性フォンビルブランド病から選ばれる疾患の出血症状に対する作用である、〔30〕に記載の使用。
〔32〕止血作用が、血友病Aの出血症状に対する作用である、〔30〕に記載の使用。
〔33〕抗血液凝固作用を阻害するための薬剤を製造するためのプロテインCの活性化阻害物質の使用。
〔34〕抗血液凝固作用が、活性化プロテインCの抗血液凝固作用である、〔33〕に記載の使用。
〔35〕プロテインCの活性化阻害物質が、さらに活性化プロテインCの活性を阻害する、〔27〕から〔34〕のいずれかに記載の使用。
〔36〕薬剤が、活性化プロテインCの活性阻害物質をさらに含む、〔27〕から〔35〕のいずれかに記載の使用。
〔37〕プロテインCの活性化阻害物質が、抗プロテインC抗体である、〔27〕から〔35〕のいずれかに記載の使用。
〔38〕抗プロテインC抗体が、プロテインCの重鎖に結合する抗体である、〔37〕に記載の使用。
〔39〕出血性疾患を治療するために使用されるプロテインCの活性化阻害物質。
〔40〕出血性疾患が血友病、後天性血友病及び、vWFの機能異常又は欠損に起因するフォンビルブランド病又は後天性フォンビルブランド病から選ばれる疾患である、〔39〕に記載の物質。
〔41〕出血性疾患が血友病Aである、〔39〕に記載の物質。
〔42〕止血作用を促進するために用いられるプロテインCの活性化阻害物質。
〔43〕止血作用が、血友病、後天性血友病及び、vWFの機能異常又は欠損に起因するフォンビルブランド病又は後天性フォンビルブランド病から選ばれる疾患の出血症状に対する作用である、〔42〕に記載の物質。
〔44〕止血作用が、血友病Aの出血症状に対する作用である、〔42〕に記載の物質。
〔45〕抗血液凝固作用を阻害するために使用されるプロテインCの活性化阻害物質。
〔46〕抗血液凝固作用が、活性化プロテインCの抗血液凝固作用である、〔45〕に記載の物質。
〔47〕プロテインCの活性化阻害物質が、さらに活性化プロテインCの活性を阻害する、〔39〕から〔46〕のいずれかに記載の物質。
〔48〕活性化プロテインCの活性阻害物質と組み合わせて用いる物質である、〔39〕から〔47〕のいずれかに記載の物質。
〔49〕プロテインCの活性化阻害物質が、抗プロテインC抗体である、〔39〕から〔48〕のいずれかに記載の物質。
〔50〕抗プロテインC抗体が、プロテインCの重鎖に結合する抗体である、〔49〕に記載の物質。
-タンパク質の構造を維持して免疫刺激が与えられ得る
-免疫抗原を精製する必要が無い
-グアニジン超遠心法(Biochemistry (1979) 18 (24), 5294-5299)
-AGPC法(Anal. Biochem. (1987) 162 (1), 156-159)
(1)ハイブリドーマから得られたcDNAによってコードされるV領域を含む抗体をプロテインCに接触させる工程、
(2)プロテインCと抗体との結合を検出する工程、および
(3)プロテインCに結合する抗体を選択する工程。
(1)哺乳類細胞、:CHO、COS、ミエローマ、BHK(baby hamster kidney)、Hela、Vero、HEK(human embryonic kidney)293など
(2)両生類細胞:アフリカツメガエル卵母細胞など
(3)昆虫細胞:sf9、sf21、Tn5など
-酵母:サッカロミセス・セレビシエ(Saccharomyces serevisiae)などのサッカロミセス(Saccharomyces)属、メタノール資化酵母(Pichia pastoris)などのPichia属
-糸状菌:アスペスギルス・ニガー(Aspergillus niger)などのアスペルギルス(Aspergillus)属
当該組込みベクターを宿主に導入して組換え細胞を樹立した後に、当該組換え細胞を培養し、当該ヒト化抗体をコードするDNAを発現させることによって、当該ヒト化抗体が当該培養細胞の培養物中に産生される(欧州特許公開EP239400、国際公開WO1996/002576参照)。
現ベクターに挿入することによって発現ベクターが作製され得る。当該発現ベクターを上記に挙げたような好適な発現細胞中に導入し、当該ヒト抗体をコードする遺伝子を発現させることにより当該ヒト抗体が取得される。これらの方法は既に公知である(国際公開WO1992/001047、WO1992/020791、WO1993/006213、WO1993/011236、WO1993/019172、WO1995/001438、WO1995/015388参照)。
また、プロテインCの活性化を阻害する物質が、同時に活性化プロテインCの活性を阻害する物質としては、例えば、抗体が挙げられる。具体的には、例えば、上述の抗プロテインC抗体のうち、さらに、活性化プロテインCの活性を阻害する作用を有する抗体を好ましい抗体として挙げることができる。より具体的には、プロテインC及び活性化プロテインCに結合する抗体が挙げられる。
なお本明細書において引用された全ての先行技術文献は、参照として本明細書に組み入れられる。
マウスプロテインCの全長翻訳領域をカバーするcDNAをマウス肝臓からPCR法により増幅した。これを鋳型に、さらにC末端にFLAG Tagを付与した『遺伝子をPCR法』により増幅し、発現ベクターへサブクローニングした。該発現ベクターをCHO細胞にトランスフェクションし、培養した。得られた培養上清から、常法に従って、マウスプロテインC-Flag蛋白を精製した。
実施例1で作製したマウスプロテインC-Flag蛋白(0.1 mg/匹)を、Freund's Complete Adjuvant(FCA、Difco Laboratories、現Becton Dickinson Co)と混合し、SDラット(2匹、日本チャールス・リバー株式会社)の片足のフットパッドへ接種した。接種の2週間後、免疫ラットより腸骨リンパ節を摘出した。摘出したリンパ節細胞を用いて、常法に従い、ハイブリドーマを作製した。ハイブリドーマの培養上清を用い、ハイブリドーマが産生する抗体のマウスプロテインC-FlagとFlagタンパクに対する結合活性をELISAに測定した。マウスプロテインCに対して特異的に結合活性を示す抗体を産生するハイブリドーマを選択した。選択したハイブリドーマを培養し、培養上清より抗マウスプロテインC抗体を、常法に従って精製した。精製抗体に関しては、実施例3、4記載の方法等でスクリーニングを実施し、マウスプロテインCの活性化及び/または活性化プロテインC活性を阻害する抗体としてMP35及びMP51を選択した。
(方法)
(1)試薬の調製
・抗マウスプロテインC抗体は、0.1%牛血清アルブミンを含むトリス緩衝生理食塩水(TBSB)にて、15、50 μg/mLに調製した。
・ヒルジン(Merck KgaA)は、TBSBにて、10 IU/mLに調製した。
・マウスプロテインC-Flag、ヒトαトロンビン(Enzyme Research Laboratories)、ウサギトロンボモジュリン(American Diagnostica)、ヒト活性化凝固第X因子(FXa、Enzyme Research Laboratories)、ヒト活性化凝固第V因子(FVa、Enzyme Research Laboratories)及びヒトプロトロンビン(Enzyme Research Laboratories)は、104 μMのリン脂質溶液(10% ホスファチジルセリン/60% ホスファチジルコリン/30% ホスファチジルエタノラミン (Avanti Polar Lipids);Okuda, M. & Yamamoto, Y. Clin. Lab. Haem. 26, 215-223 (2004)に従い調製)、8.3 mM のCaCl2、 1.7 mMのMgCl2を含むTBSB(TBCP)にて、それぞれ、24.8 μg/mL、1.48 μg/mL、14.8 μg/mL、9.66 ng/mL、2.25 ng/mL及び50 μg/mLに調製した。
・マウス活性化プロテインCは、24.8 μg/mLのマウスプロテインC-Flag、1.48 μg/mLのヒトαトロンビン、14.8 μg/mLのウサギトロンボモジュリンを各等量ずつ混合し、37℃で120分間インキュベーション後、混合溶液の3分の1容量の10 U/mLのヒルジンを添加することにより作製した。これを、TBSBにて、3333倍に希釈した。
・S-2238(CHROMOGENIX)は、精製水で4 mMに溶解後、さらに精製水で1.6 倍希釈した。
96 wellプレートに、(1)で調製したマウス活性化プロテインC 5 μLと、0.5、1.5、5、15、50、150、500 μg/mLの抗マウスプロテインC抗体 5 μLを混合し、室温にて30分間インキュベーションした。(抗体無添加群においては、抗体溶液の代わりにTBSB 5 μLと混合した。また、マウス活性化プロテインC及び抗体無添加群においては、それらの代わりにTBCP5 μL及びTBSB 5 μLと混合した。)
次いで、室温にて2.25 ng/mLのFVa 5μLを添加し、FVa不活化反応を開始させた。15分間後、残存FVa活性を評価するために、9.66 ng/mLのヒト FXa 5 μLと50 μg/mLのヒトプロトロンビン 5 μLを添加して、FVa濃度依存的なトロンビン生成反応を開始させた。10分間後、0.5 MのEDTA 5 μLを添加してトロンビン生成反応を停止させた。生成したトロンビンの活性を測定するため、発色基質溶液S-2238 5 μLを添加し、発色反応を開始させた。15分間の発色反応後、405 nmの吸光度変化をSpectraMax 340PC384(Molecular Devices)を用いて測定した。
抗マウスプロテインC抗体 MP35又はMP51は、いずれも吸光度を上昇させた(図1)。従って、MP35及びMP51共にマウス活性化プロテインCによるFVa不活化を阻害することが示された。
(方法)
(1)試薬の調製
・抗マウスプロテインC抗体及びヒルジンはTBSBにて、それぞれ120 μg/mL及び75 U/mLに調製した。
・マウスプロテインC-Flag、ヒトαトロンビン及びウサギトロンボモジュリンは、TBCPにて、それぞれ、24.8 μg/mL、14.8 μg/mL及び14.8 μg/mLに調製した。
・Spectrozyme aPC(American Diagnostica)は、精製水で5 mMに溶解後、さらに精製水で6.25 倍希釈した。
96 wellプレートに、120 μg/mLの抗マウスプロテインC抗体 5 μL、及び24.8 μg/mLのマウスプロテインC-Flag蛋白溶液 5 μLを混合し、室温にて30分間インキュベーションした。(抗体無添加群においては、抗体溶液の代わりにTBSB 5 μLと混合した。)
次いで、37℃にて14.8 μg/mLのヒトαトロンビン 5 μLと14.8 μg/mLのウサギトロンボモジュリン5 μLを添加し、マウスプロテインC活性化反応を開始させた。120分間後、75 U/mLのヒルジン10 μLを添加してプロテインC活性化反応を停止させた。生成した活性化プロテインCの活性を測定するため、発色基質溶液Spectrozyme aPC 10 μLを添加し、発色反応を開始させた。45分間の発色反応後、405 nmの吸光度変化を吸光度計SpectraMax 340PC384(Molecular Devices)を用いて測定した。
抗マウスプロテインC抗体 MP51の添加により、吸光度が低下した。一方、MP35を添加しても、吸光度の変化は示さなかった(図2)。従って、MP51はプロテインC活性化反応を阻害するが、MP35は阻害しないことが示された。なお、マウスプロテインC活性化反応中の抗体濃度は40 μg/mLである。
(方法)
(1)試薬の調製
・抗マウスプロテインC抗体は、TBSBにて、0.18、0.6、1.8、6、18、60、及び180 μg/mLに調製した。
・プロテインC活性化物質(製品名Protac、American Diagnostica Inc)は、精製水で溶解し(6 U/mL)、更にTBSで4 U/mLに調製した。
蛍光測定用96ウェルプレート(Thermo Fisher Scientific、Immulon 2HB "U" Bottom Microtiter Plates、3655)の各ウェルに、0.18、0.6、1.8、6、18、60、及び180 μg/mLの抗マウスプロテインC抗体 25 μLとマウスクエン酸血漿15 μLを混和し、室温で15分間静置した。(抗体無添加群においては、抗体溶液の代わりにTBSB 5 μLと混合した。)
次いで、4 U/mLのプロテインC活性化物質(製品名Protac、American Diagnostica Inc)40 μLと凝固開始試薬であるPPP-Reagent LOW(Thrombinoscope BV.)20 μLを添加し、37℃で15分間室温にて静置した。
なお、プロテインCをProtacで活性化させない場合のトロンビン生成を測定するため、抗体溶液の代わりに同容量のTBSB、Protacの代わりに同容量のTBSを添加したサンプルも準備した。
その後、プレートをトロンビン生成蛍光システムにセットし、37℃で約5分間インキュベーション後、測定を開始させた。(測定開始と同時に、Fluo-SubstrateとFluo-Bufferの混合溶液20 μLが添加される。)
なお、各サンプルから得られる蛍光強度をトロンビン量に換算するために、同一プレート内で、マウス血漿15 μLとTBSB 25 μLの混合溶液に、凝固開始試薬の代わりにThrombin Calibrator(Thrombinoscope BV.)20 μLを添加するウェルも設定した。
なお、トロンビン生成蛍光システム専用解析ソフトThrombinoscope software version 3.0.0.29(Thrombinoscope BV.)の設定条件は以下のとおりである。
・Fluo-SubstrateとFluo-Bufferの混合溶液量(設定項目 Dispense):20 μL
・攪拌時間(設定項目 Shake):10秒間
・測定時間(設定項目 Totaltime):60分間
・測定間隔(設定項目 Interval):20秒
・励起波長(自動設定):390 nm
・蛍光波長(自動設定):460 nm
算出されたトロンビン生成開始時間(Lag time(min))及び最大トロンビン生成量(Peak height(nmol/L))を用い、マウス血漿中における抗マウスプロテインC抗体の活性化プロテインC活性阻害能を評価した。
プロテインC活性化物質(Protac)を添加した正常マウス血漿のトロンビン生成に対する抗マウスプロテインC抗体の効果を図3Aに示した。正常マウス血漿にProtacを添加することにより、Lag timeは2.0 分から2.4 分に延長し、Peak heightは53 nMから22 nMに減少したことから、Protacで生成された活性化プロテインCが本血漿において抗凝固作用を示すことが確認された。抗マウスプロテインC抗体MP35、MP51共に用量依存的に、Protac添加時のLag timeを短縮させ、Peak heightを増加させた。
同様に、FVIII欠乏マウス血漿に関しても評価した(図3B)。FVIII欠乏マウス血漿にProtacを添加することにより、Lag timeは2.2分から2.5分に延長し、Peak heightは33 nMから15 nM減少したことから、Protacで生成された活性化プロテインCが本血漿において抗凝固作用を示すことを確認した。MP35、MP51共に濃度依存的に、Protac添加時のLag timeを短縮させ、Peak heightを増加させた。
従って、正常マウス血漿又はFVIII欠損マウス血漿において、MP35及びMP51が、活性化プロテインCの抗凝固作用を阻害することにより、凝固作用を促進するポテンシャルを有することが示された。
また、血漿におけるマウス活性化プロテインC阻害活性に関しては、MP35は、MP51に比し、同等あるいはそれ以上の活性を有していることが示された。
FVIII欠損マウス(B6;129S4-F8tm1Kaz/J mice)を、ヌードマウス(Crlj: CD1-Foxn1nu)と交配し、体毛のない表現型をFVIII欠損マウスに導入した。
(方法)
Vehicle(n = 8)、3 mg/kgの抗マウスプロテインC抗体 MP51(n = 9)、又は30 mg/kgの抗マウスプロテインC抗体 MP35(n = 9)を血友病Aマウスの尾静脈内に投与した。イソフルラン麻酔下で、マウスの左右の大腿内側部筋肉に23G注射針を3 mmの深さで2カ所ずつ穿刺した。穿刺した日をDay0とし、Day1及びDay2に体表から目視可能な出血痕の面積を計測した。Day 1、Day 2それぞれで計測された出血痕面積をマウス個体ごとに総和した出血痕総面積を測定して出血の指標とした。
Vehicle群では、穿刺による出血刺激により、時間経過とともに出血痕総面積が増加した。プロテインC活性化と活性化プロテインCの活性を阻害する抗マウスプロテインC抗体 MP51(3 mg/kg)投与群では、Day 1及びDay 2いずれにおいても、出血痕総面積の増加が抑制された。一方、活性化プロテインCの活性のみを阻害するMP35投与(30 mg/kg)群では、vehicle群と同様に出血痕総面積が増加した(図4)。従って、プロテインC活性化と活性化プロテインCの活性を阻害する抗プロテインC抗体が血友病Aにおける出血症状に対して止血効果を有することが示された。
(方法)
MP35及びMP51が、マウスPCの軽鎖、重鎖、どちらを認識するかを、western blotting(WB)を用い、検討した。マウスPC([製品名] Recombinant Mouse Coagulation Factor XIV/Protein C、[供給元] R&D Systems、 [カタログ番号] 4885-SE)をヒトトロンビン([製品名] Human alpha Thrombin、[供給元] Enzyme research laboratories、[カタログ番号] HT 1002a)及びウサギトロンボモジュリン([製品名] Rabbit Thrombomodulin、[供給元] Haematologic Technologies、[カタログ番号] RTM-2020)で活性化させ、結果生じたマウス活性化PCをSDS-PAGEした後、PVDF膜に移し、MP35又はMP51と反応させた。二次抗体([製品名] HRP-Goat anti-Rat IgG (H+L)、[供給元] Life technologies、[カタログ番号] 629520)と基質([製品名] SuperSignal West Dura Extended Duration Substrate、[供給元] サーモフィッシャーサイエンティフィック株式会社、[カタログ番号] 34076)でMP35あるいはMP51と結合する蛋白を検出した。
WBの結果、MP35は、15と20 kDa間のタンパクと結合することが示された。このタンパクは、分子量及びN末シークエンスからマウス活性化PCの軽鎖であることが確認された。一方、MP51は、37と50 kDa間のタンパクと結合することが示された。このタンパクは、分子量及びN末シークエンスから活性化マウスPCの重鎖であることが確認された。したがって、MP35はマウスPC/マウス活性化PCの軽鎖、MP51はその重鎖を認識することが示された。
実施例1で作製したマウスプロテインC蛋白を用い、ヒトナイーブ抗体ライブラリから、ファージディスプレイ法により、マウスプロテインCに結合するディスプレイファージを濃縮した。マウスプロテインCに対して特異的に結合活性を示すディスプレイファージを選択し、そこから抗体可変領域遺伝子を増幅。常法に従って遺伝子組換えIgGとして発現させ、精製した。精製抗体に関しては、実施例3、4記載の方法等でスクリーニングを実施し、マウスプロテインCの活性化及び/または活性化プロテインC活性を阻害する抗体としてL2及びL12を選択した。
(方法)
実施例3の方法に準じた。
(結果)
抗マウスプロテインC抗体 L2又はL12は、いずれも吸光度を上昇させた(図5)。従って、L2及びL12共にマウス活性化プロテインCによるFVa不活化を阻害することが示された。なお、マウスプロテインC活性化反応中の抗体濃度は15または50 μg/mLである。
(方法)
実施例4の方法に準じた。
(結果)
抗マウスプロテインC抗体 L12の添加により、吸光度が低下した。一方、L2を添加しても、吸光度の変化は示さなかった(図6)。従って、L12はプロテインC活性化反応を阻害するが、L2は阻害しないことが示された。なお、マウスプロテインC活性化反応中の抗体濃度は30 μg/mLである。
Claims (14)
- プロテインCの活性化阻害物質を含有する、出血性疾患を治療するための医薬組成物。
- 出血性疾患が血友病、後天性血友病及び、vWFの機能異常又は欠損に起因するフォンビルブランド病又は後天性フォンビルブランド病から選ばれる疾患である、請求項1に記載の組成物。
- 出血性疾患が血友病Aである、請求項1に記載の組成物。
- プロテインCの活性化阻害物質を含有する、止血作用を促進するための医薬組成物。
- 止血作用が、血友病、後天性血友病及び、vWFの機能異常又は欠損に起因するフォンビルブランド病又は後天性フォンビルブランド病から選ばれる疾患の出血症状に対する作用である、請求項4に記載の組成物。
- 止血作用が、血友病Aの出血症状に対する作用である、請求項4に記載の組成物。
- プロテインCの活性化阻害物質を含有する、抗血液凝固作用を阻害するための医薬組成物。
- 抗血液凝固作用が、活性化プロテインCの抗血液凝固作用である、請求項7に記載の組成物。
- プロテインCの活性化阻害物質が、さらに活性化プロテインCの活性を阻害する、請求項1から8のいずれかに記載の組成物。
- 医薬組成物が、活性化プロテインCの活性阻害物質と組み合わせて用いる組成物である、請求項1から9のいずれかに記載の組成物。
- プロテインCの活性化阻害物質が、抗プロテインC抗体である、請求項1から10のいずれかに記載の組成物。
- 抗プロテインC抗体が、プロテインCの重鎖に結合する抗体である、請求項11に記載の組成物。
- プロテインCの重鎖に結合し、プロテインCの活性化プロテインCへの変換を阻害する作用を有する、抗プロテインC抗体。
- 抗プロテインC抗体が、さらに活性化プロテインCの活性を阻害する作用を有する、請求項13に記載の抗体。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14845545.4A EP3047857A4 (en) | 2013-09-20 | 2014-09-19 | Treatment for hemorrhagic diseases by anti-protein-c antibody |
US15/021,718 US20160229922A1 (en) | 2013-09-20 | 2014-09-19 | Treatment for hemorrhagic diseases by anti-protein-c antibody |
JP2015537971A JP6445440B2 (ja) | 2013-09-20 | 2014-09-19 | 抗プロテインc抗体による出血性疾患の治療 |
US16/391,848 US20190248921A1 (en) | 2013-09-20 | 2019-04-23 | Treatment for hemorrhagic diseases by anti-protein-c antibody |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013195355 | 2013-09-20 | ||
JP2013-195355 | 2013-09-20 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/021,718 A-371-Of-International US20160229922A1 (en) | 2013-09-20 | 2014-09-19 | Treatment for hemorrhagic diseases by anti-protein-c antibody |
US16/391,848 Division US20190248921A1 (en) | 2013-09-20 | 2019-04-23 | Treatment for hemorrhagic diseases by anti-protein-c antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015041310A1 true WO2015041310A1 (ja) | 2015-03-26 |
Family
ID=52688957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/074789 WO2015041310A1 (ja) | 2013-09-20 | 2014-09-19 | 抗プロテインc抗体による出血性疾患の治療 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20160229922A1 (ja) |
EP (1) | EP3047857A4 (ja) |
JP (1) | JP6445440B2 (ja) |
TW (1) | TWI673063B (ja) |
WO (1) | WO2015041310A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019009407A1 (ja) * | 2017-07-07 | 2019-01-10 | 第一三共株式会社 | 抗プロテインc抗体 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020051277A1 (en) * | 2018-09-06 | 2020-03-12 | Board Of Regents, The University Of Texas System | Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr) |
Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
EP0058481A1 (en) | 1981-02-16 | 1982-08-25 | Zeneca Limited | Continuous release pharmaceutical compositions |
EP0133988A2 (de) | 1983-08-02 | 1985-03-13 | Hoechst Aktiengesellschaft | Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung |
JPS60120825A (ja) * | 1983-10-18 | 1985-06-28 | Fujisawa Pharmaceut Co Ltd | 抗プロテインcモノクロ−ナル抗体およびそれを産生するハイブリド−マ |
EP0239400A2 (en) | 1986-03-27 | 1987-09-30 | Medical Research Council | Recombinant antibodies and methods for their production |
JPH03504332A (ja) * | 1988-12-30 | 1991-09-26 | オクラホマ メディカル リサーチ ファウンデーション | プロテインcに対するモノクローナル抗体 |
WO1992001047A1 (en) | 1990-07-10 | 1992-01-23 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993009804A1 (en) * | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994011523A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Fully impaired consensus kozac sequences for mammalian expression |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1995001438A1 (en) | 1993-06-30 | 1995-01-12 | Medical Research Council | Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH10504186A (ja) * | 1994-06-10 | 1998-04-28 | オクラホマ メディカル リサーチ ファウンデーション | プロテインcに対するカルシウム結合組換え抗体 |
WO2004009641A1 (ja) * | 2002-07-22 | 2004-01-29 | Chugai Seiyaku Kabushiki Kaisha | aPC非中和抗体 |
US7291333B1 (en) * | 1992-07-24 | 2007-11-06 | Oklahoma Medical Research Foundation | Blockade of protein C activation reduces microvascular surgical blood loss |
WO2008081008A1 (en) | 2007-01-05 | 2008-07-10 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
JP2011500843A (ja) | 2007-10-26 | 2011-01-06 | オクラホマ・メディカル・リサーチ・ファウンデーション | 活性化プロテインcおよび不活性化プロテインcに対するモノクロナール抗体 |
-
2014
- 2014-09-19 EP EP14845545.4A patent/EP3047857A4/en not_active Withdrawn
- 2014-09-19 JP JP2015537971A patent/JP6445440B2/ja not_active Expired - Fee Related
- 2014-09-19 WO PCT/JP2014/074789 patent/WO2015041310A1/ja active Application Filing
- 2014-09-19 TW TW103132396A patent/TWI673063B/zh not_active IP Right Cessation
- 2014-09-19 US US15/021,718 patent/US20160229922A1/en not_active Abandoned
-
2019
- 2019-04-23 US US16/391,848 patent/US20190248921A1/en not_active Abandoned
Patent Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
EP0058481A1 (en) | 1981-02-16 | 1982-08-25 | Zeneca Limited | Continuous release pharmaceutical compositions |
EP0133988A2 (de) | 1983-08-02 | 1985-03-13 | Hoechst Aktiengesellschaft | Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung |
JPS60120825A (ja) * | 1983-10-18 | 1985-06-28 | Fujisawa Pharmaceut Co Ltd | 抗プロテインcモノクロ−ナル抗体およびそれを産生するハイブリド−マ |
EP0239400A2 (en) | 1986-03-27 | 1987-09-30 | Medical Research Council | Recombinant antibodies and methods for their production |
JPH03504332A (ja) * | 1988-12-30 | 1991-09-26 | オクラホマ メディカル リサーチ ファウンデーション | プロテインcに対するモノクローナル抗体 |
WO1992001047A1 (en) | 1990-07-10 | 1992-01-23 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993009804A1 (en) * | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US7291333B1 (en) * | 1992-07-24 | 2007-11-06 | Oklahoma Medical Research Foundation | Blockade of protein C activation reduces microvascular surgical blood loss |
WO1994011523A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Fully impaired consensus kozac sequences for mammalian expression |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1995001438A1 (en) | 1993-06-30 | 1995-01-12 | Medical Research Council | Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
JPH10504186A (ja) * | 1994-06-10 | 1998-04-28 | オクラホマ メディカル リサーチ ファウンデーション | プロテインcに対するカルシウム結合組換え抗体 |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO2004009641A1 (ja) * | 2002-07-22 | 2004-01-29 | Chugai Seiyaku Kabushiki Kaisha | aPC非中和抗体 |
WO2008081008A1 (en) | 2007-01-05 | 2008-07-10 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
JP2011500843A (ja) | 2007-10-26 | 2011-01-06 | オクラホマ・メディカル・リサーチ・ファウンデーション | 活性化プロテインcおよび不活性化プロテインcに対するモノクロナール抗体 |
Non-Patent Citations (32)
Title |
---|
"Remington's Pharmaceutical Science", 1980 |
"Remington's Pharmaceutical Science", MARK PUBLISHING COMPANY |
ANAL. BIOCHEM., vol. 162, no. 1, 1987, pages 156 - 159 |
ASTERMARK J., HAEMOPHILIA, vol. 9, no. 1, 2003, pages 32 |
BERNASCONI ET AL., SCIENCE, vol. 298, 2002, pages 2199 - 2202 |
BIO/TECHNOLOGY, vol. 12, no. 7, 1994, pages 699 - 702 |
BIOCHEMISTRY, vol. 18, no. 24, 1979, pages 5294 - 5299 |
BUTENAS S ET AL., J THROMB HAEMOST, vol. 4, 2006, pages 2411 |
C. EUR. J. IMMUNOL., vol. 6, no. 7, 1976, pages 511 - 519 |
CANCER RES., vol. 53, 1993, pages 851 - 856 |
CASTELLINO FJ; PLOPLIS VA, J THROMB AND HAEMOST, vol. 7, no. 1, 2009, pages 140 |
CELL, vol. 8, no. 3, 1976, pages 405 - 415 |
CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, vol. 81, 1978, pages 1 - 7 |
J. EXP. MED., vol. 148, no. 1, 1978, pages 313 - 323 |
J. IMMUNOL. METHODS, vol. 35, no. 1-2, 1980, pages 1 - 21 |
J. IMMUNOL., vol. 123, no. 4, 1979, pages 1548 - 1550 |
KOHLER; MILSTEIN ET AL., METHODS ENZYMOL, vol. 73, 1981, pages 3 - 46 |
LANGER ET AL., J. BIOMED. MATER. RES., vol. 15, 1981, pages 267 - 277 |
LANGER, CHEMTECH., vol. 12, 1982, pages 98 - 105 |
MESTERS, R. M. ET AL.: "Identification of a sequence of human activated protein C (residues 390-404) essential for its anticoagulant activity", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 36, 1991, pages 24514 - 24519, XP055328931 * |
NATURE, vol. 276, no. 5685, 1978, pages 269 - 270 |
NATURE, vol. 277, no. 5692, 1979, pages 131 - 133 |
NUCLEIC ACIDS RES., vol. 17, no. 8, 1989, pages 2919 - 2932 |
OKUDA, M.; YAMAMOTO, Y., CLIN. LAB. HAEM., vol. 26, 2004, pages 215 - 223 |
PROC. NATL. ACAD. SCI. USA, vol. 85, no. 23, 1988, pages 8998 - 9002 |
SAMBROOK, J. ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOR LAB. PRESS, pages: 9.47 - 9.58 |
SCHLACHTERMAN A ET AL., J THROMB HAEMOST, vol. 3, 2005, pages 2730 |
See also references of EP3047857A4 |
SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 556 |
SUZUKI, K. ET AL.: "Monoclonal Antibodies to Human Protein C : Effects on the Biological Activity of Activated Protein C and the Thrombin-Catalyzed Activation of Protein C", JOURNAL OF BIOCHEMISTRY, vol. 97, no. 1, 1985, pages 127 - 138, XP008091703 * |
VAN DIJK K ET AL., J THROMB AND HAEMOST, vol. 92, 2004, pages 305 |
VANDAMME ET AL., EUR. J. BIOCHEM., vol. 192, no. 3, 1990, pages 767 - 775 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019009407A1 (ja) * | 2017-07-07 | 2019-01-10 | 第一三共株式会社 | 抗プロテインc抗体 |
Also Published As
Publication number | Publication date |
---|---|
JP6445440B2 (ja) | 2018-12-26 |
US20160229922A1 (en) | 2016-08-11 |
US20190248921A1 (en) | 2019-08-15 |
EP3047857A1 (en) | 2016-07-27 |
TW201609131A (zh) | 2016-03-16 |
JPWO2015041310A1 (ja) | 2017-03-02 |
EP3047857A4 (en) | 2017-08-09 |
TWI673063B (zh) | 2019-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240052059A1 (en) | Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii | |
US9090697B2 (en) | Methods for treating bleeding disorders | |
US20220089778A1 (en) | Coagulation factor binding proteins and uses thereof | |
JP2003527861A (ja) | 増強した抗血液凝固能を持つ抗組織因子抗体 | |
US20160297892A1 (en) | Novel Methods and Antibodies for Treating Coagulapathy | |
WO2021043206A1 (zh) | 一种抗tigit免疫抑制剂及应用 | |
TWI716059B (zh) | 經改良的促凝血抗體 | |
TW202110890A (zh) | 抗siglec-9組合物及其用於調節骨髓細胞發炎表型之方法及用途 | |
TW201212938A (en) | Antibodies that are capable of specifically binding tissue factor pathway inhibitor | |
TW201925225A (zh) | 可調整配體結合活性的配體結合分子 | |
RU2603097C2 (ru) | Антитела к р-селектину и способы их применения и идентификации | |
TW202210523A (zh) | 用於調節骨髓樣細胞發炎表型之抗vsig4組合物及方法以及其用途 | |
TW200407335A (en) | Non-neutralizing antibody to inhibit the inactivation of activated protein C | |
US20190248921A1 (en) | Treatment for hemorrhagic diseases by anti-protein-c antibody | |
TW202110891A (zh) | 抗psgl-1組合物及其用於調節骨髓細胞發炎表型之方法及用途 | |
US8252287B2 (en) | Blood coagulation factor VIII activation-enhancing antibodies | |
WO2019200357A1 (en) | Biomarker for cd47 targeting therapeutics and uses therefor | |
TW201906868A (zh) | 抗蛋白c抗體 | |
RU2818588C2 (ru) | Биспецифические антитела | |
WO2021210667A1 (ja) | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 | |
TW202208443A (zh) | 蛋白質s抗體、其製造方法及其用途 | |
US20210309746A1 (en) | Antibodies that bind cd277 and uses thereof | |
TW201617371A (zh) | 針對經活化之因子v之抗體 | |
WO2023159220A1 (en) | Anti-cd47 antibodies | |
WO2020115283A1 (en) | Bispecific antibodies binding factor ixa and factor x |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14845545 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015537971 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15021718 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014845545 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014845545 Country of ref document: EP |